Journal article

Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1

  • Luethy, Anita Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
  • Stenner, Frank Department of Oncology, University Hospital Zurich, Switzerland
  • Lohri, Corinne Department of Oncology, University Hospital Zurich, Switzerland
  • Muller, Christoph Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
  • Samaras, Panagiotis Department of Oncology, University Hospital Zurich, Switzerland
  • Steiner, Rudolf Department of Oncology, University Hospital Zurich, Switzerland
  • Broek, Maries Van Den Department of Oncology, University Hospital Zurich, Switzerland
  • Mischo, Axel Department of Oncology, University Hospital Zurich, Switzerland
  • Renner, Christoph Department of Oncology, University Hospital Zurich, Switzerland
  • Knuth, Alexander Department of Oncology, University Hospital Zurich, Switzerland
  • Rüegg, Curzio Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
  • Wenger, Roland H. Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
  • Zweifel, Martin Department of Oncology, University Hospital Zurich, Switzerland
Show more…
    2011
Published in:
  • Anticancer Research. - 2011, vol. 31, no. 10, p. 3115-3124
English Background: High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. In this study, we measured the effect of HDC/ASCT on plasma concentrations of antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) angiogenesis. Materials and Methods: VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR. Results: Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1+ neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform. Conclusion: Neutrophil- derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
Other electronic version

Publisher's version

License
License undefined
Identifiers
  • RERO DOC 28471
Persistent URL
https://folia.unifr.ch/unifr/documents/302469
Statistics

Document views: 11 File downloads:
  • rue_acs.pdf: 3